Clinical Report: Comparative Analysis of Ivermectin and Chemotherapy Agents

Overview

This study evaluates the effectiveness of ivermectin combined with recombinant methioninase (rMETase) against human colon cancer cells compared to five standard chemotherapeutic agents combined with rMETase. Ivermectin demonstrated significantly greater efficacy than four of the five chemotherapy agents in this context.

Background

Colorectal cancer is a leading cause of cancer-related morbidity and mortality worldwide. Traditional chemotherapy has limitations in efficacy and survival outcomes, prompting the exploration of novel agents like ivermectin. The combination of ivermectin with rMETase targets methionine addiction in cancer cells, potentially enhancing treatment effectiveness.

Data Highlights

Key Findings

• Ivermectin combined with rMETase was significantly more effective than rMETase combined with 5-fluorouracil, cisplatinum, gemcitabine, and paclitaxel.
• The chemosensitivity index for ivermectin + rMETase was 6.7 ± 1.9.
• Doxorubicin combined with rMETase showed a CI of 7.8 ± 1.7, slightly more effective than ivermectin + rMETase.
• All treatments were assessed at their half-maximal inhibitory concentrations (IC50).
• The study utilized HCT116 human colon-cancer cells for testing.

Clinical Implications

The findings suggest that ivermectin, when combined with rMETase, may offer a more effective treatment option for colon cancer compared to several standard chemotherapeutic agents. Further clinical investigation is warranted to explore the potential of this combination in therapeutic settings.

Conclusion

Ivermectin combined with rMETase demonstrates superior efficacy against colon cancer cells compared to multiple standard chemotherapy agents, indicating its potential as a promising anticancer strategy.

Related Resources & Content

1. Combined Neoadjuvant Therapy Utilizing Immune Checkpoint Inhibition, Anti-Angiogenic Agents, and Chemotherapy Improves Pathological Outcomes and Survival Rates in Locally Advanced and Metastatic Colorectal Cancer: Findings from a Multicenter Study
2. Monotherapy with sorafenib or 5-FU demonstrates comparable efficacy in human colorectal cancer xenografts—no advantage observed with combination treatment
3. Hepatic Arterial Infusion of Cetuximab Combined with Oxaliplatin Effectively Inhibits Growth of CC531 Colorectal Liver Metastases, Unlike Systemic Administration
4. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
5. Selective Synergy of Ivermectin Combined With Recombinant Methioninase Against Colon-Cancer Cells in Contrast to Normal Fibroblasts
6. Journal of Neuro-Oncology — Inhibition of Class I HDACs Impairs DNA Repair Mechanisms in MYC-Enhanced Medulloblastoma Cells
7. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up - PubMed
8. Selective Synergy of Ivermectin Combined With Recombinant Methioninase Against Colon-Cancer Cells in Contrast to Normal Fibroblasts - PubMed